Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.56 |
| ▸ | CNR2 | P34972 | 6/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672829 | 0.88 | CNR1 (0.61) | CNR1CNR2PPARA | |
| SCHEMBL29838956 | 0.76 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL923180 | 0.76 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL923308 | 0.76 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL972368 | 0.75 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL4187487 | 0.75 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL277240 | 0.75 | CNR1 (0.59) | CNR1CNR2PPARA | |
| SCHEMBL17163901 | 0.74 | CNR2 (0.62) | CNR1CNR2 | |
| SCHEMBL923181 | 0.74 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL2865960 | 0.74 | CNR1 (0.61) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514068-B2 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885PPARA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.